Vol. 3 No. 2 (1997)
Case Report

Clinical Assessment of Alzheimer’s Disease and Response to Donepezil Treatment

PDF
  • Serge Gauthier
DOI: https://doi.org/10.26443/mjm.v3i2.423

Published 2020-12-01

Keywords

  • Alzheimer's,
  • donepezil

How to Cite

1.
Gauthier S. Clinical Assessment of Alzheimer’s Disease and Response to Donepezil Treatment. McGill J Med [Internet]. 2020 Dec. 1 [cited 2025 Oct. 6];3(2). Available from: https://mjm.mcgill.ca/article/view/423
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Abstract

N/A

PDF

Downloads

Download data is not yet available.

References

  1. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12(3): 189- 198; 1975.
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington DC: American Psychiatric Association; 1994.
  3. Gauthier S, Panisset M, Nalbantoglu J, Poirier J. Alzheimer’s disease: current knowledge, management andcresearch. Canadian Medical Association Journal 157(8): 1047-1052; 1997.
  4. Thalman B, Mansch AU, Ermini-Fiinfshilling D et al. Improved screening for dementia: combining the Clock Drawing Test and the Mini-Mental Status Examination. Presented at the 4th International Nice/Springfield Alzheimer Symposium, Nice, April 10-14th 1996.
  5. Organizing Comittee, Canadian Consensus Confgerence on the Assessment of Dementia. Canadian Medical Association Journal 144: 851-853; 1991.
  6. Fontaine S, Nordberg A. Brain imaging. In: Clinical Diagnosis and Management of Alzheimer’s Disease. Gauthier S, ed., London: Martin Dunitz Ltd; 1996: 83-106.
  7. Gauthier S, Burns A, Pettit W. Alzheimer’s Disease in Primary Care. London: Martin Dunitz Ltd;1997.
  8. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes ijn Alzheimer’s disease. Neurology 49(1): 38-43; 1997.
  9. Communicating the diagnosis. In: Tough Issues. Alzheimer Society of Canada; 1997.
  10. Keyserlingk EW, Glass K, Kogan S, Gauthier S. Proposed guidelines for the participation of persons with dementia as research subjects. Perspectives in Biology and Medicine 38: 319-362; 1995.
  11. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double- blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136-145; 1998.
  12. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. European Neuropsychopharmacology 8: 67- 75; 1998.
  13. Gauthier S. Treatment strategies for Alzheimer’s disease. McGill Journal of Medicine 3(2): 149-152; 1998